NCT06929507View on ClinicalTrials.gov

Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients

NARecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

March 10, 2026

Study Completion Date

March 10, 2027

Conditions
Renal Function DisorderDiabetic Macular Edema (DME)Neovascular Age Related Macular Degeneration
Interventions
DRUG

Intravitreal injection of Faricimab or Aflibercept 2 mg

Anti-VEGF agents Faricimab (Vabysmo) or Aflibercept 2 mg (Eylea) will be delivered intravitreally

Trial Locations (2)

68100

RECRUITING

University Hospital of Alexandroupolis, Alexandroupoli

COMPLETED

University Hospital of Alexandroupolis, Alexandroupoli

All Listed Sponsors
lead

University Hospital, Alexandroupolis

OTHER